Global Antihypertensive Drugs Market Share Is Likely To Reach At A CAGR Value Of Around 2.95% By 2030

05-Jan-2023 | Facts and Factors

According to Facts and Factors, the global antihypertensive drugs market size was worth around USD 20.5 billion in 2021 and is predicted to grow to around USD 39.5 billion by 2030 with a compound annual growth rate (CAGR) of roughly 2.95% between 2022 and 2030.

Hypertension or high blood pressure is a medical condition that is related to the intensity and force of the blood pressure which is related to the pressure exerted by blood on the walls of the arteries which are responsible for carrying the blood to different parts of the body. There are two numbers that are used to measure blood pressure. The first is called systolic blood pressure and it is the number indicating the pressure of the blood on the arteries when the heart is beating. The second number is called diastolic blood pressure and this value indicates the pressure exerted when the heart is resting between two beats.

Browse the full “Antihypertensive Drugs Market By Disease Source (Secondary Hypertension and Primary Hypertension), By Therapeutics (Angiotensin Receptor Blockers (ARBs), Diuretics, Beta Blockers, Angiotensin Converting Enzyme (ACE), Calcium Channel Blockers, Alpha Blockers, Vasodilators, and Renin Inhibitors), By End-Users (Clinics, Hospitals, and Homecare), and By Region - Global and Regional Industry Insights, Overview, Comprehensive Analysis, Trends, Statistical Research, Market Intelligence, Historical Data and Forecast 2022 – 2030" report at https://www.fnfresearch.com/antihypertensive-drugs-market

Normal blood pressure is 120/80 mmHg and any value above this is regarded as high blood pressure with different stages involved depending on the pressure value. The condition is informally referred to as the ‘silent killer’ because there is no way to detect the problem apart from checking the blood pressure regularly.

The global antihypertensive drugs market is projected to grow due to increasing development in new drugs as well as the growing market for generic medicine. Hypertension is a common medical problem and it is not restricted to only certain regions across the globe. It can occur in any person irrespective of age and ethnicity. The number of antihypertensive drug consumers remains high due to the widespread nature of the disease. This has led to more players entering the market as well as investing in strategic measures to enter new markets.

In November 2022, Horizon Therapeutics, a rare disease drug maker, announced that it has received buyout applications from major pharmaceutical giants like Johnson & Johnson, Amgen, and Sanofi. The company is currently undergoing preliminary discussions with all three. In the same year, Pfizer acquired Biohaven Pharmaceuticals for USD 11.6 billion, making the deal one of the most expensive buyouts of 2022.

One of the major factors leading to restricted growth in the global market is the low success rate of medicines. A study published by the National Library of Medicine concluded that after undergoing regular medical treatments for hypertension, the success rate was only 50%. The current medications are not 100% effective in controlling the conditions. The same study also quoted that blood pressure reduced below 140/90 mmHg in only one-fourth of the US Citizens undertaking medicines for hypertension. Although there are factors like the non-commitment of the patient to the treatment, the low efficacy rate remains a major concern.

The increasing research & development could provide higher growth opportunities while managing side effects associated with antihypertensive drugs could challenge the market expansion.

Segmental Overview

The global antihypertensive drugs market is segmented based on disease source, therapeutics, end-users, and region

Based on disease source, the global market divisions are secondary hypertension and primary hypertension. In 2021, the global market was dominated by the latter due to higher reported cases and subsequent demand for accurate medical assistance. As per official reports, primary hypertension accounts for nearly 95% of all cases related to high blood pressure.

In case, the cause of hypertension is not known, it is called primary hypertension however, there are certain influential risk factors like a sedentary lifestyle, smoking, improper management of stress, obesity, and poor diet. It is recommended to regularly get a blood pressure check since it remains impossible to zero down on one particular cause.

Based on therapeutics, the global market divisions are angiotensin receptor blockers (ARBs), diuretics, beta-blockers, angiotensin-converting enzyme (ACE), calcium channel blockers, alpha-blockers, vasodilators, and renin inhibitors. Angiotensin Receptor Blockers (ARBs) are used extensively to relax arteries and veins by lowering blood pressure. They help the heart in pumping blood easily. The initial dose of the ARBs should be 80 mg orally.

Regional Overview

North America is projected to lead the global antihypertensive drugs market owing to the growing rate of obesity and sedentary lifestyle choices. Hypertension is associated with other diseases as well related to the kidney, heart, and brain. It is considered a leading cause of premature death by the WHO and is as common as 1 in every 4 men and 1 in every 5 women. There are a variety of reasons that could trigger the condition and some of them are unhealthy diet, poor lifestyle choices, and lack of physical activity.

could lead to higher numbers of patients being detected with hypertension further propelling market demand. As per official data, more than 41% of US citizens are obese which is around one-third of the population. Growth in Asia-Pacific is projected to be led by the growing expansion of the regional pharmaceutical industry with higher dominance of generic medicines.

Report Scope

Competitive Landscape

The global antihypertensive drugs market is led by players like Sanofi S.A, F. Hoffmann-La Roche Ltd., Daiichi Sankyo Company, Limited, Pfizer, Inc., and Actelion Ltd.

Recent Developments:

• In April 2021, Minearalys Therapeutics, a biopharmaceutical start-up, raised over USD 40 million through the sale of private stock. The funds will be directed toward a proof-of-concept study which is its second phase of experimental hypertension treatment
• In October 2019, Boehringer Ingelheim, a dominating pharmaceutical company, announced that it will start domestic production of antihypertensive medicine in Algeria

The global antihypertensive drugs market is segmented as follows:

By Disease Source 

• Secondary Hypertension
• Primary Hypertension

By Therapeutics 

• Angiotensin Receptor Blockers (ARBs)
• Diuretics
• Beta Blockers
• Angiotensin Converting Enzyme (ACE)
• Calcium Channel Blockers
• Alpha Blockers
• Vasodilators
• Renin Inhibitors

By End-Users 

• Clinics
• Hospitals
• Homecare

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Nordic Countries
    • Denmark
    • Sweden
    • Norway
  • Benelux Union
    • Belgium
    • The Netherlands
    • Luxembourg
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Southeast Asia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Rest of Southeast Asia
  • Rest of Asia Pacific
• The Middle East & Africa
  • Saudi Arabia
  • UAE
  • Egypt
  • South Africa
  • Rest of the Middle East & Africa
• Latin America
  • Brazil
  • Argentina
  • Rest of Latin America

About Us:

Facts & Factors is a leading market research organization offering industry expertise and scrupulous consulting services to clients for their business development. The reports and services offered by Facts and Factors are used by prestigious academic institutions, start-ups, and companies globally to measure and understand the changing international and regional business backgrounds. Our client’s/customer’s conviction on our solutions and services has pushed us in delivering always the best. Our advanced research solutions have helped them in appropriate decision-making and guidance for strategies to expand their business.

Contact Us:
Facts & Factors
A 2108, Sargam,
Nanded City,
Sinhagad Road,
Pune 411041, India
USA: +1 (347) 690-0211
Email: [email protected]
Web: https://www.fnfresearch.com